RevBio Secures A Key Patent for Innovative Bone Adhesive
RevBio, a pioneering clinical stage medical device company based in Lowell, has recently received acclaim for securing a vital patent for its groundbreaking TETRANITE bone adhesive technology. The United States Patent and Trademark Office has issued patent number 12,178,937 titled “Compositions and Methods for Adhesion to Surfaces.” This important milestone signifies the 10th U.S. patent granted to RevBio, showcasing its commitment to advancing bone repair innovations.
Technological Innovations in Bone Adhesives
This newly awarded patent is notable for incorporating injectable mineral-organic structural compositions containing alpha tricalcium phosphate, expanding the applications of their existing technologies. TETRANITE biomaterial stands out not only for its innovative composition but also for its inclusion of phosphoserine, an organic component known for its significant role in bone regeneration, emphasizing its unique position in the regenerative medicine field.
Expert Insights on Patent Importance
George Kay, Chief Scientific Officer and co-founder of RevBio, expressed his enthusiasm regarding this patent grant. He noted that it solidifies RevBio's intellectual property portfolio in the mineral-organic bone adhesive domain. Kay explained that the TETRANITE biomaterial combines exceptional handling properties, impressive weight-bearing strength, and high biocompatibility, creating a robust solution with real potential for medical applications.
Strategic Partnerships and Future Directions
In an effort to drive its advancements further, RevBio, formerly known as LaunchPad Medical, has secured an exclusive worldwide patent license from Stryker Corporation. This partnership spans six patent families that encompass both the bone adhesive technology and its specific applications. The agreements provide valuable patent protection until 2033, positioning RevBio to not only develop but also market TETRANITE-based products effectively.
Commitment to Growth and Development
Since 2016, RevBio has made significant strides in securing its intellectual property by filing fourteen Patent Cooperation Treaty applications. Many of these applications are set to protect their bone adhesive solutions until 2043. With four of these applications already granted U.S. patents, several others are in various stages of prosecution across the United States and internationally. This strategic approach ensures that RevBio is well-prepared to address the global market challenges and opportunities.
Anticipating Impact on Market and Patients
As RevBio continues to build on its innovations, it is poised to make a substantial impact in the medical landscape. The CEO and founder, Brian Hess, emphasized that receiving this key patent is a significant achievement. It enhances the company's core value while providing a competitive advantage for investors who support the growth and development of this transformative technology.
About RevBio, Inc.
RevBio, Inc. is dedicated to developing and commercializing its patented TETRANITE technology, which serves as a synthetic, injectable, self-setting, and osteoconductive bone adhesive. With an eye on orthopaedic markets and applications within the animal health sector, RevBio aims to harness its innovative solutions in various clinical contexts. It is important to note that RevBio's products are currently not approved for commercial use, but the future looks promising with ongoing developments and enhancements in its technology.
Frequently Asked Questions
What is the significance of RevBio's new patent?
The patent enhances RevBio's competitive edge and protects their innovative bone adhesive technology.
How does TETRANITE stand out from other bone adhesives?
TETRANITE is unique for including phosphoserine, which contributes to bone regeneration processes.
What markets is RevBio targeting?
RevBio is focusing on dental, cranial, orthopaedic, and animal health markets with its TETRANITE technology.
What is the role of Stryker Corporation in RevBio’s advancements?
Stryker Corporation provides RevBio with an exclusive worldwide patent license that supports their technology development.
When is RevBio expected to launch its products?
Although not yet approved for commercial use, RevBio is actively developing its products with a focus on future release timelines.
